[Correlation of CD4/CD8Ratio in Peripheral Blood with Prognosis of Mantle Cell Lymphoma].

OBJECTIVE

To investigate the correlation of peripheral blood T lymphocyte subsets with overall survival (OS) and clinical baseline characteristics in mantle cell lymphoma (MCL).

METHODS

The clinical data of 55 MCL patients who were newly diagnosed in the Department of Hematology, Second Hospital of Shanxi Medical University from January 2012 to July 2022 were analyzed retrospectively. The percentages of T lymphocyte subsets and CD4/CD8 ratio in peripheral blood were detected by flow cytometry, and their correlation with clinical characteristics of patients were analyzed. Kaplan-Meier method was used for survival analysis and survival curves were drawn. Log-rank test was used for univariate analysis, while Cox proportional hazards model was used for multivariate analysis.

RESULTS

The median follow-up was 40(1-68) months, and the median overall survival (OS) was 47 months. Among the 55 patients, 30(54.5%) patients had a decrease in peripheral blood CD4T lymphocyte, while 17(30.9%) patients had a increase in peripheral blood CD8T lymphocyte, and 20(36.4%) patients had a decrease in CD4/CD8 ratio. There were no significant correlations between CD4/CD8 ratio and sex, age, Ki-67, B symptoms, leukocytes, hemoglobin, lymphocytes, platelets, albumin, lactate dehydrogenase (LDH), β-microglobulin, splenomegaly, bone marrow invasion, primary site and MIPI score. Survival analysis showed that patients with CD4T cell >23.3%, CD8T cell ≤33.4% and CD4/CD8 ratio >0.6 had longer OS ( =0.020, <0.001, <0.001). Univariate analysis showed that Ki-67>30%, LDH>250 U/L, splenomegaly, bone marrow involvement, CD4T cells ≤23.3%, CD8 T cells >33.4%, CD4/CD8 ratio ≤0.6 were adverse prognostic factors affecting OS of MCL patients. Multivariate analysis showed that CD4/CD8 ratio ≤0.6 ( =4.382, =0.005) was an independent adverse prognostic factor for OS of MCL patients.

CONCLUSIONS

Low CD4/CD8 ratio is associated with poor prognosis in MCL, and the CD4/CD8 ratio can be used as an important indicator to evaluate the prognosis risk in MCL patients.